$TLN — Talen Energy is executing a major capital return and leadership transition, locking in future cash flows to aggressively shrink its share count. We peeled the 8-K. TLN monetized $1.5 billion of future PJM capacity revenues, selling contracted cash flow at SOFR + 200 bps. This isn't just a cash raise; it's immediate deployment. Those proceeds are already funding a $1.5 billion accelerated share repurchase (ASR) with Goldman Sachs and Banco Santander. At current prices, this ASR retires over 10% of outstanding shares. This is highly accretive for remaining holders. The board didn't stop there; total repurchase authorization is now upsized to $3.0 billion through 2028, building on prior programs. A leadership shift is also underway. Terry Nutt, President and former CFO, steps into the CEO role effective January 1, 2027, succeeding Mac McFarland. This move brings forward significant contracted cash flows while preserving TLN's liquidity and keeping the path clear for its 3.5x net leverage target by the second half of 2027. It’s a coordinated play: optimize cash flow, return capital, and solidify leadership. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$HUT — An officer/director at HUT just moved to sell a staggering $139 million in shares. Michael Ho filed a Form 144 for 1.5 million shares, priced at $93. This isn't a direct market dump. It's a prepaid forward agreement with an entity he controls, Springtide Creek Ltd. This structure allows him to monetize his position now while deferring actual share delivery. Still, it represents a massive overhang on the stock. The timing is critical. This filing comes after a significant run for Hut 8, following securing major AI data center contracts and a fresh $1.07 billion senior secured revolving credit facility just last week. We've flagged that HUT recently announced contracting 949 MW of AI infrastructure, with an internal estimate of $26.6 billion in long-term contracts. This move is near recent highs and follows a series of positive announcements. We’ve also been tracking an ongoing insider distribution pattern, with over $2.5 million in net insider selling (excluding this filing) in the last 90 days. While personal diversification is a common reason, the sheer size of this transaction and its timing demand serious attention for HUT investors. Most won't catch this until it's priced in. Source & full breakdown: Wiseek (link in bio)

$TSLA — just secured a massive $30 billion in new credit facilities, confirmed by a recent regulatory filing. This includes a $20 billion delayed draw term loan, providing substantial liquidity. The move significantly funds Tesla's aggressive capital expenditure plans and its critical robotaxi initiative. We flagged this need. The company's Q2 2026 results showed negative free cash flow of $1.1 billion and a staggering 142% year-over-year surge in capex. This new financing, which replaces an existing $5 billion revolving credit facility, substantially reduces near-term liquidity risk and signals strong confidence from lenders in Tesla's growth strategy. Investors now watch how quickly Tesla draws on these facilities and whether its ambitious robotaxi program meets rollout targets. This is a clear runway for their next phase of expansion. Peeled it before the move. Source & full breakdown: Wiseek (link in bio)

$EUDA — is flashing a critical red flag. Management issues a formal going concern warning, citing substantial doubt about the company's ability to survive the next year. This follows a dire H1 2026, where the company booked an $0.80M net loss and holds a meager $0.37M cash. Operating cash flow for the period was negative $1.2M, continuing a pattern of recurring losses since 2020. The balance sheet currently appears propped up by a $7.56M crypto asset position. We peeled this transaction: 16M QB Tokens were acquired in May 2026, partly in exchange for 500,000 shares valued at $7.31M. Before this acquisition, total assets stood at $1.7M; the crypto pushed them to $9.7M. Critically, these crypto assets are valued using Level 3 unobservable inputs, with no active market, raising serious questions about their realizable value. Despite a recent $3.75M private placement at $6.00/share, the underlying financial distress is undeniable. The going concern language signals a deep-seated issue, highlighting persistent negative operating cash flow and a history of relying on related-party financing. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$JAGX — Jaguar Health JAGX is asking shareholders to approve a package of highly dilutive financing measures that could hand control of the company to CVP affiliates and wipe out existing equity holders. We peeled the PRER14A filing outlining proposals for a November 6 special meeting. Proposal 1 alone would allow for the full exchange of Series Q Preferred Stock and CVP Debt, issuing up to 25.4 million new shares at a $1.00 exchange price. This represents a staggering 92.9% increase over the 1.95 million shares currently outstanding, giving CVP affiliates roughly 65% control. On top of this, Proposal 2 seeks to reprice 4,052 warrants from as high as $3,996.60 down to $1.00, unlocking an additional 49,690 shares, or 8.7% dilution. Further, Proposal 5 would slash the ELOC floor price from $16.50 to an unspecified lower level, opening the door for C/M Capital to buy shares at deeply depressed prices. These actions come just 12 days after a 1-for-15 reverse split, making the proposed dilution even more impactful. This aggressive move, alongside an existing going-concern warning and just $3.8M cash, signals JAGX is exhausting every available avenue to raise capital. With the stock currently trading at $5.20, this package of proposals — including a potential reverse split up to 1-for-150 and an equity plan expansion to 14% — points to massive shareholder dilution and a significant shift in ownership control. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$DYN — z-basivarsen delivers durable functional gains in DM1, crucial data separating it from natural history. This 8-K confirms one-year ACHIEVE trial data, a significant de-risking event for the program. At 6 months, the pooled dose group (N=25-26) showed a 3.2-second vHOT improvement versus a 0.4-second worsening for placebo. Critically, 12-month data showed treated patients diverging from natural history cohorts on QMT total, hand grip, and 10-meter walk/run – a first for Dyne and a strong indicator of disease modification. We peeled the numbers: MDHI total score improved 25.2%, well beyond the minimal clinically important difference. This strengthens the case for z-basivarsen's impact. The registrational expansion cohort (N=71) is fully enrolled with a mean baseline vHOT of 8.3 seconds. This sets the stage for a Q1 2027 topline readout, potentially supporting a U.S. Accelerated Approval BLA submission by Q3 2027. Safety remains favorable with no related serious adverse events, despite insiders selling nearly $90M in the last 90 days. This is more than just symptom stabilization; it's a confirmed shift in disease progression. With over $1.3B in cash from their last Q2 and recent offering, DYN has the runway to execute this pipeline. Traders should mark Q1 2027 and Q3 2027 on their calendars. Most won't catch this until it's priced in. Source & full breakdown: Wiseek (link in bio)

$BTDR — H1 2026 brought a $251.8 million net loss for BTDR. Operating loss hit $208.3 million as depreciation and electricity costs surged past revenue growth. This 6-K formalized the massive $4.7 billion Volta Tydal colocation deal, backstopped by a $1.3 billion credit. Plus, a new $100 million cash land acquisition in Texas was unveiled. We've been watching the capital requirements closely. Despite a cash boost to $456.8 million, the company carries heavy convertible and related-party debt. These new, large-scale commitments alongside existing ATM dilution point to persistent capital expenditure and share overhang risk. The path to profitability for BTDR is getting steeper. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

🍌 News on $DPRO (Draganfly) · Sep 28, 07:45 ET Lands $10M Strategic Investment from Unusual Machines and U.S. Fund Reported at $5.55 → Now $6.28 (+13.2%) Watch the breakdown 👇 🟢 Score 9/10 Source: Wiseek (link in bio)

$PSKY — The $110 billion Warner Bros. Discovery merger financing just hit its major execution phase. PSKY launched the investment-grade bond sale, the largest component of its $52 billion debt package. This isn't just talk; this is capital hitting the market. We flagged the $44.4 billion notes offering in the September 28th 8-K, signaling this move. This debt package is the critical piece to close the $110 billion acquisition. With the major regulatory hurdles now largely settled – we peeled those settlements earlier this week – the focus shifts to financing execution. What to watch next? Pricing details and final allocation. Market confidence in the deal's completion will be signaled by those terms and investor demand. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$PIPR — is in serious talks to acquire Perella Weinberg Partners. This isn't just industry chatter — a deal could finalize in weeks, fundamentally reshaping the advisory landscape. We peeled this as a major consolidation play, merging Piper's established middle-market strength with Perella's robust larger-cap M&A franchise. This acquisition significantly broadens PIPR's market footprint. The timing is strategic. Piper Sandler just posted a strong Q2, with net revenues up 25% to $496 million, demonstrating a solid financial position for expansion. An acquisition of Perella Weinberg would undoubtedly come at a premium, signaling PIPR's aggressive growth strategy. Watch for confirmation of definitive deal terms and any potential regulatory hurdles. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$GPRK — GeoPark GPRK is committing $7 billion to Venezuela's Bare oilfield, targeting a massive production surge. This move aims to nearly triple company-wide output to 75,000-85,000 boe/d by 2030, a significant jump from current levels. The Venezuela play alone is projected to hit 90,000 bpd by 2038, up from just 11,000 bpd. This ambitious plan involves reactivating 1,100 wells and drilling 80 new horizontal wells across four phases. GPRK has about $700 million in liquidity, including $310 million cash, to fund the initial stages. We flagged the Bare block entry and Gilinski equity financing back in September; this new announcement provides concrete scale and a timeline to that expansion. While the project offers a substantial boost to GeoPark's growth trajectory, traders must factor in the significant geopolitical and execution risks inherent in Venezuela. The upside is clear, but so is the complexity. Peeled it before the move. Source & full breakdown: Wiseek (link in bio)

$IRT — Activists are moving to derail the $8.1 billion all-stock merger between IRT and Centerspace. Ancora Holdings, holding roughly 2% of Independence Realty Trust, plans to vote against the deal. They're pushing the board for a sale of IRT itself, eyeing a target of $18-$20 per share. That's a 22-36% premium over the current $14.71 price. This isn't just noise; another significant shareholder, Irenic, also opposes the merger, citing a lack of industrial logic. The market reaction to the initial merger announcement on September 9 already sent IRT shares down 4.3%. Now, with two significant shareholders publicly opposing the current terms, the board faces serious pressure to find a better path. Ancora's proposed $18-$20 per share sale price sets a clear benchmark for what shareholders demand. This activist push could force the board to explore alternatives, potentially putting the entire merger at risk and creating volatility for both companies involved. Investors should watch for further statements or potential proxy battles. Most won't catch this until it's priced in. Source & full breakdown: Wiseek (link in bio)

$NEOG — FDA just slammed NEOG with a warning letter regarding its Hycoat product, citing serious fungal contamination. The agency alleges misbranding, mislabeling, and insanitary manufacturing, directly linking the product to approximately 100 horse joint infections and at least 20 deaths. This news broke with shares at $13.46. While Neogen initiated a voluntary recall of Hycoat back in January, this formal FDA action, delivered September 23rd, significantly escalates the regulatory pressure. The warning letter directly follows a year where the company's 10-K highlighted ongoing product recall liabilities, positioning this as a critical hit to an already challenged animal health segment. The clock is ticking for Neogen: they have 15 days to respond with corrective actions. Failure to adequately address these severe allegations could lead to further enforcement and prolonged impact on their operations. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$LHX — L3Harris just locked in a massive $6 billion contract over seven years from Lockheed Martin for THAAD propulsion production. This is a material positive, immediately adding substantial backlog and clear revenue visibility for LHX, directly fueling their missile segment growth. We caught this. This isn't a standalone event. This award builds directly on a July framework agreement with Lockheed and the Department of War, and follows September's $4.7 billion PAC-3 propulsion contract. It firmly cements LHX's position as a core propulsion supplier in the defense sector. Against a Q2 2026 reported backlog of $42 billion, this $6 billion commitment significantly reinforces their long-term revenue stream and validates the earlier $1 billion DoW investment in their missile capabilities. The market often sees defense contracts as steady, but this specific string of wins for LHX, especially on propulsion, points to an accelerating trend. Strong Q2 revenue growth of 8% YoY and EPS up 28% YoY already set a high bar. This $6 billion secures a significant portion of future growth, giving investors long-term confidence in the defense giant's trajectory. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$PWP — Acquisition talks sent PWP shares rocketing 11% to $16.2. Piper Sandler is reportedly eyeing Perella Weinberg. We peeled this report shortly after it hit, a significant shift for the advisory firm. This isn't just chatter. A $1.4 billion market cap target for a $5 billion suitor like Piper Sandler suggests a substantial transaction, if finalized. While Piper Sandler's shares dipped 3.1% on the news, PWP shareholders stand to gain a premium. Talks could still fall apart, but this is a new, material development. Watch for deal finalization. A successful acquisition would combine two mid-sized investment banks. Peeled it before the move. Source & full breakdown: Wiseek (link in bio)

🍌 $IOVA (Iovance Biotherapeutics) filed an 8-K · Sep 29, 07:05 ET Iovance Lifts FY2026 Revenue Guidance to $410-$420M, a $55M Midpoint Increase Filed at $11.25 → Now $13.70 (+21.8%) Banancial breakdown 👇 🟢 Score 8/10 Source: Wiseek (link in bio)

$CCL — Carnival CCL just delivered its highest-ever Q3 net income: $1.92 billion on $8.44 billion in revenue. This record performance led to a guidance raise for FY26 adjusted net income by over $150 million, now targeting approximately $3.08 billion. Demand is the key driver here, with record customer deposits up nearly 7% despite flat capacity. We caught this initial data earlier when the company filed its 8-K. The company expects Q4 adjusted net income to be around $274 million. Capital return remains a priority, with $1.2 billion in share repurchases year-to-date signaling continued shareholder value. The market is recognizing the improved profitability: CCL now trades at 9x forward earnings, a re-rating from 12x just three months ago. The next critical watch point is sustained booking momentum into Q4. Also, keep an eye on any commentary regarding fuel cost pressures. Peeled it before the move. Source & full breakdown: Wiseek (link in bio)

$FICO — FICO's mortgage credit scoring monopoly is under direct assault. The FHFA just mandated a single pricing grid for Fannie Mae and Freddie Mac, officially integrating VantageScore alongside FICO Classic. This isn't just regulatory noise; it's the direct threat we've been watching since Director Pulte's September 4 monopoly accusation. Mortgage origination pricing was a huge tailwind, driving FICO's fiscal Q3 2026 Scores revenue up 41% and overall revenue 26%. This overhaul targets that critical revenue stream head-on. FICO is down 18% premarket, near 52-week lows. The market is unwinding years of unchallenged dominance today. We peeled this threat as regulatory pressure escalated. Now it's a concrete policy shift. Watch closely for implementation details and lender adoption rates. The competitive dynamics in mortgage scoring have fundamentally changed. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$MTUS — A $125 million concrete revenue commitment just landed for MTUS. This isn't theoretical contract ceiling — it's a first firm delivery order under the $995 million defense agreement we flagged just days ago. This initial $125 million commitment is substantial. For context, MTUS reported Q2 sales of $341 million. This order provides significant near-term revenue visibility, with the company having up to 24 months to fulfill it. The Defense Logistics Agency is showing clear intent to utilize the broader five-year contract, despite the $995 million being an uncommitted ceiling. We’re watching for further orders, but this confirms the DLA's commitment. This solidifies the revenue runway for their defense segment. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$QMLS — $240.9 million in new AI inference contracts just peeled away significant risk for QMLS. These two three-year take-or-pay agreements cover over 2,000 NVIDIA Blackwell B300 GPUs. This directly addresses the going-concern doubt we flagged in their last 10-Q. Multi-year revenue is now locked in. These are expanded commitments, not entirely new customers. The larger $211.9 million deal comes from an AI inference platform that had previously committed $71.9 million. A second $29.1 million deal is with a generative-AI platform that had a $32 million commitment. Total contracted value with these two customers now exceeds $344 million. This adds significant weight to the pro forma backlog of ~$276 million reported just last week, which itself was up 59% from Q2's $173.1 million RPO. Capacity turnover is targeted for December 2026 and early 2027. Expect revenue recognition to ramp over the next year. This news derisks a key vulnerability for QMLS. Peeled it before the move. Source & full breakdown: Wiseek (link in bio)